- Home
- MREO vs SCLX Comparison
MREO vs SCLX Comparison
Compare MREO & SCLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MREO | SCLX |
|---|---|---|
| Founded | 2015 | 2011 |
| Country | United Kingdom | United States |
| Employees | N/A | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 52.9M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | MREO | SCLX |
|---|---|---|
| Price | $0.33 | $6.96 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 27.1K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $6,000.20 | N/A |
| Revenue Next Year | $34.71 | $749.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $3.60 |
| 52 Week High | $2.94 | $34.27 |
Technical Indicators
Market Signals| Indicator | MREO | SCLX |
|---|---|---|
| Relative Strength Index (RSI) | 41.57 | 42.00 |
| Support Level | $0.32 | $6.20 |
| Resistance Level | $0.42 | $7.76 |
| Average True Range (ATR) | 0.02 | 0.51 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 42.31 | 45.83 |
Price Performance
Historical ComparisonAbout MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
About SCLX Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.